文献速递糖尿病

脂蛋白(a)血浆水平与2型糖尿病微血管并发症发生无关

Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus.
PubMed 文献 · Diabetologia · 2020-03-09

该研究基于荷兰埃因霍温DiaGene前瞻性研究1886例2型糖尿病患者(平均随访6.97年),采用Cox比例风险模型分析血浆脂蛋白(a)水平及LPA基因SNP rs10455872和rs3798220与新发微血管并发症的关系,未发现显著关联,但LPA SNPs确可影响血浆脂蛋白(a)水平。

要点

  • 血浆脂蛋白(a)水平与2型糖尿病新发视网膜病变、肾病、神经病变均无显著关联。
  • LPA基因SNP rs10455872和rs3798220与新发微血管并发症无显著关联。
  • LPA SNPs rs10455872和rs3798220确实影响血浆脂蛋白(a)水平,与既往观察一致。

核心结论

  • 数据显示血浆脂蛋白(a)水平及对其有已知影响的LPA SNPs与2型糖尿病微血管并发症的发生无关,提示脂蛋白(a)在微血管并发症发生中不发挥主要作用,但需更大规模研究以排除其微小效应。

研究设计与样本

  • 基于荷兰埃因霍温DiaGene前瞻性研究数据,纳入1886例2型糖尿病患者,平均随访6.97年。
  • 采用Cox比例风险模型分析血浆脂蛋白(a)水平及LPA SNPs rs10455872和rs3798220与新发微血管并发症的关系,并校正年龄、性别、平均动脉压、非HDL胆固醇、HDL胆固醇、BMI、2型糖尿病病程、HbA1c和吸烟等危险因素。

主要发现

  • 新发视网膜病变223例、肾病246例、神经病变236例。
  • 血浆脂蛋白(a)水平及LPA SNPs rs10455872和rs3798220与2型糖尿病微血管并发症的患病或新发均无显著关联。
  • LPA SNPs rs10455872和rs3798220确实影响血浆脂蛋白(a)水平,与既往观察一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模的研究来排除脂蛋白(a)对微血管并发症发生的微小效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Microvascular disease in type 2 diabetes is a significant cause of end-stage renal disease, blindness and peripheral neuropathy. The strict control of known risk factors, e.g. lifestyle, hyperglycaemia, hypertension and dyslipidaemia, reduces the incidence of microvascular complications, but a residual risk remains. Lipoprotein (a) [Lp(a)] is a strong risk factor for macrovascular disease in the general population. We hypothesised that plasma Lp(a) levels and the LPA gene SNPs rs10455872 and rs3798220 are associated with the incident development of microvascular complications in type 2 diabetes. METHODS: Analyses were performed of data from the DiaGene study, a prospective study for complications of type 2 diabetes, collected in the city of Eindhoven, the Netherlands (n = 1886 individuals with type 2 diabetes, mean follow-up time = 6.97 years). To assess the relationship between plasma Lp(a) levels and the LPA SNPs with each newly developed microvascular complication (retinopathy n = 223, nephropathy n = 246, neuropathy n = 236), Cox proportional hazards models were applied and adjusted for risk factors for microvascular complications (age, sex, mean arterial pressure, non-HDL-cholesterol, HDL-cholesterol, BMI, duration of type 2 diabetes, HbA1c and smoking). RESULTS: No significant associations of Lp(a) plasma levels and the LPA SNPs rs10455872 and rs3798220 with prevalent or incident microvascular complications in type 2 diabetes were found. In line with previous observations the LPA SNPs rs10455872 and rs3798220 did influence the plasma Lp(a) levels. CONCLUSIONS/INTERPRETATION: Our data show no association between Lp(a) plasma levels and the LPA SNPs with known effect on Lp(a) plasma levels with the development of microvascular complications in type 2 diabetes. This indicates that Lp(a) does not play a major role in the development of microvascular complications. However, larger studies are needed to exclude minimal effects of Lp(a) on the development of microvascular complications.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Singh SS, Rashid M, Lieverse AG, et al. Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus. Diabetologia. 2020. PMID: 32152647. doi:10.1007/s00125-020-05120-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。